These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 24507058)

  • 41. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium.
    Kamar N; Oufroukhi L; Faure P; Ribes D; Cointault O; Lavayssiere L; Nogier MB; Esposito L; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Oct; 20(10):2231-6. PubMed ID: 16046517
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: a pilot study.
    Dumortier J; Gagnieu MC; Salandre J; Guillaud O; Guillem P; Adham M; Boillot O
    Liver Transpl; 2006 Sep; 12(9):1342-6. PubMed ID: 16741931
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enteric-coated mycophenolate sodium: one-way conversion from mycophenolate mofetil and de novo use in stable liver transplant recipients.
    Nure E; Magalini SC; Frongillo F; Barbarino R; Pepe G; Avolio AW; Agnes S
    Transplant Proc; 2009 May; 41(4):1290-2. PubMed ID: 19460541
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mycophenolic acid in kidney transplant patients with diabetes mellitus: does the formulation matter?
    Bolin P; Gohh R; Kandaswamy R; Shihab FS; Wiland A; Akhlaghi F; Melancon K
    Transplant Rev (Orlando); 2011 Jul; 25(3):117-23. PubMed ID: 21530217
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The evaluation of enteric-coated mycophenolate sodium in cardiac deceased donor liver transplant patients in China.
    Wang Z; He JJ; Liu XY; Lin B; Zhang L; Geng L; Zheng S
    Immunopharmacol Immunotoxicol; 2015; 37(6):508-12. PubMed ID: 26525836
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
    Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
    Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients.
    Sollinger H
    Transplant Proc; 2004 Mar; 36(2 Suppl):517S-520S. PubMed ID: 15041399
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tolerance of enteric-coated mycophenolate sodium in combination with calcineurin inhibitor in kidney transplant recipients: Polish experience.
    Gozdowska J; Urbanowicz AL; Galazka Z; Chmura A; Durlik M
    Transplant Proc; 2011 Oct; 43(8):2946-9. PubMed ID: 21996197
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: conversion to enteric-coated mycophenolate sodium.
    Calvo N; Sanchez-Fructuoso AI; Conesa J; Moreno A; Barrientos A
    Transplant Proc; 2006 Oct; 38(8):2396-7. PubMed ID: 17097945
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study.
    Budde K; Knoll G; Curtis J; Kahana L; Pohanka E; Seifu Y; Neumayer HH
    Transplant Proc; 2005 Mar; 37(2):912-5. PubMed ID: 15848573
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improvement in Severe Mycophenolic Acid-associated Gastrointestinal Symptoms after Changing Enteric-coated Mycophenolate Sodium to Mizoribine in Renal Transplant Recipients: Two Case Reports.
    Liu H; Wang Y; Fan B; Ren L; Wang W; Hu P; Zhang X
    Intern Med; 2016; 55(15):2005-10. PubMed ID: 27477406
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Mycophenol acid in ocular automimmune disorders--can we optimise this therapy?].
    Pleyer U; Ruokonen P; Schmidt N; Feist E; Höhne M; Stanojlovic S
    Klin Monbl Augenheilkd; 2008 Jan; 225(1):66-9. PubMed ID: 18236373
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients.
    Salvadori M; Holzer H; Civati G; Sollinger H; Lien B; Tomlanovich S; Bertoni E; Seifu Y; Marrast AC;
    Clin Nephrol; 2006 Aug; 66(2):112-9. PubMed ID: 16939067
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation.
    Belliere J; Esposito L; Gandia P; Duffas JP; Sallusto F; Cardeau-Desangles I; Del Bello A; Rostaing L; Kamar N
    Ann Transplant; 2014 Feb; 19():76-81. PubMed ID: 24509827
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of conversion from mycophenolate mofetil to mycophenolate sodium among renal transplant recipients on a sirolimus-based regimen.
    Kahan BD; Podbielski J; Childs B
    Transplant Proc; 2008 Jun; 40(5):1429-34. PubMed ID: 18589123
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil.
    Arns W; Breuer S; Choudhury S; Taccard G; Lee J; Binder V; Roettele J; Schmouder R
    Clin Transplant; 2005 Apr; 19(2):199-206. PubMed ID: 15740555
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
    Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gastrointestinal disorders after renal transplantation.
    Savvidaki E; Papachristou E; Kazakopoulos P; Papasotiriou M; Vardoulaki M; Goumenos DS
    Transplant Proc; 2014 Nov; 46(9):3183-6. PubMed ID: 25420854
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enteric-coated mycophenolate sodium experience in liver transplant patients.
    Cantisani GP; Zanotelli ML; Gleisner AL; de Mello Brandão A; Marroni CA
    Transplant Proc; 2006 Apr; 38(3):932-3. PubMed ID: 16647514
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of conversion of mycophenolate mofetil to enteric-coated mycophenolate sodium in Mexican renal transplant children.
    Reyes H; Hernández AM; Valverde S; Cataneo A; Mendoza A; Barrera I; Ortíz L; García-Roca P; Lopéz-Martínez B; Castañeda-Hernández G; Medeiros M
    Pediatr Transplant; 2010 Sep; 14(6):746-52. PubMed ID: 20412508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.